Savara Inc Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Savara Inc (SVRA) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2013-11-04
- 2013-09-30: Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month $0.00.
- 2012-09-30: Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month |
|---|---|
| 2013-09-30 | $0.00 10-Q · filed 2013-11-04 |
| 2012-09-30 | $0.00 10-Q · filed 2013-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |